Neumora Therapeutics Inc. (NASDAQ: NMRA) announced that its phase 3 KOASTAL-2 and KOASTAL-3 studies of navacaprant for major depressive disorder ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE